Succinobucol(AGI 1067)

产品编号: DC10581 Featured
Succinobucol(AGI 1067)
结构式
216167-82-7
此产品仅供科研所需,我们不出售给病人
​我们将匹配市场上最好的价格给您
Email:order@dcbio.cn
免费咨询电话:4008862077
我们的合作伙伴:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
中国地区超过5000个高品质化合物库存
应用领域
Succinobucol 是一种酚类抗氧化剂,具有抗炎、抗血小板聚集的作用。
Cas No.: 216167-82-7
名称:
别名: Succinobucol; AGI-1067; AGZ-1067; AGI1067; AGZ1067. Probucol monosuccinae
SMILES: O=C(O)CCC(OC1=C(C(C)(C)C)C=C(SC(C)(SC2=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C2)C)C=C1C(C)(C)C)=O
分子式: C35H52O5S2
分子量: 616.91
纯度:
保存条件: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description:
In Vivo:
In Vitro:
References: In Vitro: Succinobucol (10, 50, 100 μM) causes a dose-dependent reduction in collagen-induced platelet aggregation in rabbit whole blood. Succinobucol also causes a significant reduction in whole blood aggregation in response to ADP. Succinobucol (10, 100 μM) significantly lowers the relaxation to X/XO. Succinobucol significantly prevents 3-NP-induced loss of SH-SY5Y cell viability, generation of reactive oxygen species, and decrease of ΔΨm. Succinobucol does not protect against 3-NP-induced inhibition of mitochondrial complex II activity, pointing to the mitigation of secondary events resultant from mitochondrial complex II inhibition. Succinobucol significantly increases (50 %) the levels of GSH in SH-SY5Y cells, which is paralleled by significant increases in glutamate cysteine ligase messenger RNA (mRNA) expression and activity. Succinobucol effectively exhibits superior inhibitory effects on cell migration and invasion activities, VCAM-1 expression and cell-cell binding of RAW 264.7 to 4T1 cells. Succinobucol also shows inhibitory effect on VCAM-1 expression in 4T1 cells and cell-cell binding of RAW 264.7 to 4T1 cancer cells. In Vivo: Succinobucol (50, 100, and 150 mg/kg, i.v.) has no significant effect on either heart rate or MAP, but the blood removed 15 minutes after the final injection of succinobucol shows significantly less aggregation in response to collagen at both 5 µg/mL and 20 µg/mL in rats. Succinobucol (40 mg/kg) by tail injection significantly reduces the average number of metastatic nodules in lung metastatic breast cancer mice.
Kinase Assay:
Cell Assay:
Animal Administration:
References:
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
产品编号 产品名称 应用领域
DC7515 Teglicar Teglicar 是选择性和可逆性的肉毒碱棕榈酰转移酶 1 (L-CPT1) 肝异构体抑制剂,可减少酮生成和葡萄糖生成,降低糖异生,改善葡萄糖稳态。Teglicar 具有潜在的抗高血糖特性。
DC10581 Succinobucol(AGI 1067) Succinobucol 是一种酚类抗氧化剂,具有抗炎、抗血小板聚集的作用。